Zobrazeno 1 - 10
of 100
pro vyhledávání: '"J. A. Bristol"'
Autor:
Steven Hubert, John F. Kokai-Kun, Giovanni Widmer, Annie Jones, Todd Parsley, Nur A. Hasan, Sheila Connelly, Perrti Koski, J. Andrew Bristol, Michael Kaleko, Saul Tzipori, Poorani Subramanian, Joseph Sliman
Publikováno v:
Anaerobe. 41:58-67
The gut microbiome, composed of the microflora that inhabit the gastrointestinal tract and their genomes, make up a complex ecosystem that can be disrupted by antibiotic use. The ensuing dysbiosis is conducive to the emergence of opportunistic pathog
Autor:
J. Andrew Bristol, Heidi Whalen, John F. Kokai-Kun, Joseph Sliman, Kenneth C. Lasseter, Olivia Coughlin, Tracey Roberts, Steven Hubert, Barbara Valero Lopez, James Longstreth
Publikováno v:
Clinical Drug Investigation. 36:725-734
SYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous β-lactam antibiotics like cephalosporins. SYN-004 is intended to degrade residual antibiotics excreted into the intestine as a result o
Autor:
Lillian F. Mayberry, C. Barton Behravesh, Ana Flisser, Karen F. Snowden, J. R. Bristol, J. Martínez-Ocaña, Victor M. Cardenas, Kristina D. Mena
Publikováno v:
Annals of Tropical Medicine & Parasitology. 102:325-333
Taenia solium and T. saginata are zoonotic tapeworms of substantial medical and economic importance. Although human taeniasis is widely recognised as an endemic problem in Mexico, its presence in the United States is poorly understood. The first popu
Publikováno v:
International journal of toxicology. 35(3)
SYN-004 is a first in class, recombinant β-lactamase that degrades β-lactam antibiotics and has been formulated to be administered orally to patients receiving intravenous β-lactam antibiotics including cephalosporins. SYN-004 is intended to degra
Autor:
Hong Ji, David L. Ennist, Mingzhu Zhu, J. Andrew Bristol, Mervat Mina, Suzanne Forry-Schaudies, Yuefeng Xie
Publikováno v:
Journal of Virology. 79:5455-5465
Historically, the adenoviral E3 region was found to be nonessential for viral replication in vitro. In addition, adenoviruses whose genome was more than approximately 105% the size of the native genome were inefficiently packaged. These profound obse
Autor:
Paul L. Hallenbeck, J. Andrew Bristol, Kiran Sakhuja, Dawn B. Kayda, Michael Kaleko, Yvette Hudson, John L. Jakubczak, Sheila Connelly, David L. Ennist, Kevin D. Burroughs
Publikováno v:
Cancer Gene Therapy. 11:92-102
Oncolytic adenoviral vectors selectively replicate in and lyse human tumor cells, providing a promising means for targeted tumor destruction. However, oncolytic vectors have limited capacity for incorporation of additional genetic material that could
Autor:
Daniel P. Rossignol, Maureen A. Mullarkey, J R Bristol, Tsutomu Kawata, Fabian Gusovsky, Melinda Przetak, Akufumi Kimura, William J. Christ, Jesse Chow, Jeffrey Rose, Seiichi Kobayashi
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 304:1093-1102
Alpha-D-glucopyranose,3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono-beta-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-1-(dihydrogen phosphate), tetrasodium salt (E5564) is
Publikováno v:
The Journal of Immunology. 167:4286-4292
In this study, we developed a mouse model of adoptive immunotherapy reflecting immune recognition of syngeneic tumor cells naturally expressing an endogenous rejection Ag. Specifically, in a pulmonary metastases model, we examined the potency and mai
Publikováno v:
Cellular Immunology. 205:73-83
Mutations in ras proto-oncogenes are commonly found in a diversity of malignancies and may encode unique, non-self epitopes for T cell-mediated antitumor activity. In a BALB/c (H-2(d)) murine model, we have identified a single peptide sequence derive
Publikováno v:
Molecular Therapy. 2:223-232
While much is known about adenovirus biology from its development as a therapeutic gene delivery vehicle, an important question remains regarding the appropriate in vivo vector dose. We describe here an in vivo dose threshold effect with an adenovira